Dynavax Technologies Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Dynavax Technologies Stock Forecast and Price Target
The average price target for Dynavax Technologies's stock lately set by several renowned analysts is $24.50, which would result in a potential upside of approximately 114.54% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $29.00 and a low estimate of $20.00. If you're interested in DVAX stock, it's important to compare it to other companies in the industry.
114.54% Upside
Dynavax Technologies Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Dynavax Technologies's Price has fallen from $0.97 to $0.00 – a 100.00% decrease. In the next year, analysts predict that Fair Value will reach $0.30 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 6.72% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.27 | Buy/Sell | $87.82 | 22.57% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.41 | Buy/Sell | £17.30 | 18.83% |
Dynavax Technologies Revenue Forecast for 2023 - 2025 - 2030
Dynavax Technologies's Revenue has grown in the last three years, jumping from $46.55M to $232.28M – an increase of 398.99%. In the next year, analysts predict that Revenue will reach $289.78M – an increase of 24.75%. For the next seven years, the forecast is for Revenue to grow by 253.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 11.25% |
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$106.18 | Buy/Sell | $135.42 | 17.16% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$86.71 | Buy/Sell | $123.75 | 15.95% |
.jpg)
Dynavax Technologies EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Dynavax Technologies's EBITDA has gone down from $-60.74M to $-26.11M – a 57.01% drop. In the next year, 1 analysts estimate that Dynavax Technologies's EBITDA will decrease by 231.79%, reaching $34.41M. According to professional forecasts, in 2030, Dynavax Technologies's EBITDA will decrease by 1025.66%, reaching $241.69M.
Dynavax Technologies EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Dynavax Technologies's EBIT has fallen from $-67.52M to $-30.45M – a 54.90% decrease. According to 3 analysts, Dynavax Technologies's EBIT will fall by 87.06% in the next year, reaching $-3.94M. Professionals believe that By 2030, Dynavax Technologies's EBIT will fall to $110.54M – a 463.01% decrease from its current value.
Dynavax Technologies EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Dynavax Technologies's EPS has fallen from $0.61 to $0.00 – a 100.00% decrease. In the next year, analysts predict that EPS will reach $0.19 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)